SEC Filing Summary: Klotho Neurosciences, Inc. (KLTO)
Business Context and Reporting Period
This Form 8-K was filed by Klotho Neurosciences, Inc., a Delaware corporation and emerging growth company, on September 25, 2025, reporting events occurring on September 19, 2025. The registrant is headquartered in Charlotte, NC, and its common stock and warrants trade on The Nasdaq Stock Market LLC under the symbols KLTO and KLTOW, respectively.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate agreement amendment and does not contain financial statement data.
Material Changes
On September 19, 2025, the Company entered into an Amendment to a Subscription Agreement originally dated June 13, 2024, with Meteora Special Opportunity Fund I, LP and related entities. The material changes include:
- Extension of the Agreement term to September 19, 2025.
- Fixing the maximum number of shares applicable to the Agreement at 6,755,000.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors beyond the standard disclosure that the description of the Amendment is qualified by reference to the full text of the document filed as Exhibit 4.1. No unusual items or contingencies were disclosed in the summary text.
Investor Verification Checklist
- Verify the full terms of the Amendment to the Subscription Agreement in Exhibit 4.1.
- Confirm the current status of the 6,755,000 share cap and whether any shares have been issued under the amended terms.
- Review the original June 13, 2024 Subscription Agreement to understand the baseline terms prior to this amendment.
- Check for any subsequent filings regarding the exercise of warrants (KLTOW) or additional capital raises.